Bioventus Inc. (NYSE:BVS) Shares Bought by Oberweis Asset Management Inc.

Oberweis Asset Management Inc. boosted its stake in Bioventus Inc. (NYSE:BVS - Free Report) by 17.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 601,714 shares of the company's stock after buying an additional 90,800 shares during the quarter. Oberweis Asset Management Inc. owned approximately 0.74% of Bioventus worth $6,318,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its stake in shares of Bioventus by 228.3% in the third quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company's stock worth $3,032,000 after acquiring an additional 176,442 shares during the last quarter. State Street Corp boosted its position in Bioventus by 38.8% during the third quarter. State Street Corp now owns 676,501 shares of the company's stock worth $8,084,000 after acquiring an additional 189,216 shares during the last quarter. Barclays PLC grew its stake in Bioventus by 24.2% during the 3rd quarter. Barclays PLC now owns 50,654 shares of the company's stock valued at $606,000 after acquiring an additional 9,854 shares in the last quarter. Geode Capital Management LLC lifted its stake in Bioventus by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 940,496 shares of the company's stock worth $11,241,000 after purchasing an additional 65,374 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Bioventus by 11.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 435,344 shares of the company's stock valued at $4,571,000 after purchasing an additional 45,182 shares in the last quarter. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group reiterated a "buy" rating and issued a $15.00 target price on shares of Bioventus in a report on Monday, March 17th.

Bioventus Trading Down 4.5 %

Shares of NYSE:BVS traded down $0.34 during mid-day trading on Wednesday, reaching $7.22. 98,744 shares of the company were exchanged, compared to its average volume of 449,673. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The firm's 50-day simple moving average is $8.91 and its 200 day simple moving average is $10.40. Bioventus Inc. has a 1 year low of $3.90 and a 1 year high of $14.38. The firm has a market cap of $591.64 million, a price-to-earnings ratio of -11.84 and a beta of 0.92.

Insider Activity

In other news, CFO Mark Leonard Singleton sold 3,875 shares of the business's stock in a transaction dated Friday, April 11th. The stock was sold at an average price of $7.57, for a total transaction of $29,333.75. Following the completion of the transaction, the chief financial officer now directly owns 141,088 shares of the company's stock, valued at approximately $1,068,036.16. The trade was a 2.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Anthony D'adamio sold 4,380 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the sale, the senior vice president now directly owns 118,178 shares in the company, valued at approximately $1,204,233.82. This trade represents a 3.57 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 24,208 shares of company stock valued at $226,138. 32.90% of the stock is currently owned by corporate insiders.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.